These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37216734)

  • 21. A review of squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Abhilasha N; Bafna UD; Pallavi VR; Rathod PS; Krishnappa S
    Indian J Cancer; 2016; 53(4):612-614. PubMed ID: 28485364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant transformation arising from mature ovarian cystic teratoma: A case series.
    Qin L; Zhao T; Liu X; Wang H; Gu X; Chen D; Wang Z; He D
    Medicine (Baltimore); 2021 Apr; 100(13):e24726. PubMed ID: 33787574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases.
    Sakuma M; Otsuki T; Yoshinaga K; Utsunomiya H; Nagase S; Takano T; Niikura H; Ito K; Otomo K; Tase T; Watanabe Y; Yaegashi N
    Int J Gynecol Cancer; 2010 Jul; 20(5):766-71. PubMed ID: 20973266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
    Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of frozen sections and serum markers in invasive squamous cell carcinoma arising from ovarian mature cystic teratoma: two case reports.
    Tazo Y; Yoshimura Y; Shoda T; Kyushima N; Okada T; Yamazaki H
    J Med Case Rep; 2016 Jan; 10():20. PubMed ID: 26801904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
    Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review.
    Miyasaka A; Nishikawa T; Kozawa E; Yasuda M; Fujiwara K; Hasegawa K
    Case Rep Oncol; 2016; 9(2):331-7. PubMed ID: 27462234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    Heitz F; Ataseven B; Staniczok C; Denkert C; Rhiem K; Hahnen E; Heikaus S; Moubarak M; Welz J; Dagres T; Vrentas V; Bommert M; Schneider S; Concin N; Harter P
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
    Ngoi NYL; Tan DSP
    ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
    Montero-Macias R; Koual M; Crespel C; Le Frére-Belda MA; Hélène HB; Nguyen-Xuan HT; Garinet S; Perkins G; Balay V; Durdux C; Florin M; Péré H; Bats AS
    J Med Case Rep; 2021 Apr; 15(1):210. PubMed ID: 33888155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
    Fennell DA; Porter C; Lester J; Danson S; Blackhall F; Nicolson M; Nixon L; Gardner G; White A; Griffiths G; Casbard A
    EClinicalMedicine; 2022 Oct; 52():101595. PubMed ID: 35990583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant transformation arising from mature cystic teratoma of the ovary presenting as ovarian torsion: a case report and literature review.
    Toba N; Takahashi T; Ota K; Takanashi A; Iizawa Y; Endo Y; Furukawa S; Soeda S; Watanabe T; Mizunuma H; Fujimori K; Takeichi K
    Fukushima J Med Sci; 2020 Apr; 66(1):44-52. PubMed ID: 32161199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Évolution des traitements adjuvants des cancers de l'ovaire].
    Pautier P
    Rev Prat; 2022 Jun; 72(6):633-637. PubMed ID: 35899664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature.
    Goudeli C; Varytimiadi A; Koufopoulos N; Syrios J; Terzakis E
    Gynecol Oncol Rep; 2017 Feb; 19():27-30. PubMed ID: 28050596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbon ion radiotherapy for recurrent malignant transformation from mature cystic teratoma of the ovary.
    Ito Y; Morikawa S; Kato S; Kajiyama H; Nawa A; Kikkawa F
    J Obstet Gynaecol Res; 2012 May; 38(5):880-3. PubMed ID: 22449402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    Chiang YC; Lin PH; Cheng WF
    Front Oncol; 2021; 11():675972. PubMed ID: 34722237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.